Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeNeurolief Ltd.

Neurolief Ltd.

Neurolief’s Relivion™ Digital Therapeutics Brain Neuromodulation Technology Featured at Headache Symposium in Israel

1/9/19: The address, titled “The New Acute Care Medications and Devices for Migraine and Cluster Headache,” included preliminary results of a randomized, double-blind, parallel group, sham-controlled clinical trial of Neurolief’s Relivion migraine treatment device. The study investigated the safety and performance of the device in delivering non-invasive combined occipital and trigeminal neurostimulation for treatment of migraine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy